Announcement • Jun 30
Edan Instruments, Inc. to Report First Half, 2026 Results on Aug 26, 2026 Edan Instruments, Inc. announced that they will report first half, 2026 results on Aug 26, 2026 Announcement • Mar 30
Edan Instruments, Inc. Launches Edan Nano Ob Assist, An Ai-Enabled Handheld Ultrasound System Edan Instruments, Inc. announced the launch of EDAN Nano OB Assist, an AI-enabled handheld ultrasound system designed to expand access to essential prenatal screening in low-resource and underserved settings. Unveiled at a launch event in Nairobi on March 23, 2026 attended by healthcare professionals, Ministry of Health representatives, NGOs, and regional partners, EDAN Nano OB Assist introduces a simplified approach to obstetric ultrasound through AI-enabled blind sweep technology, enabling caregivers to obtain key clinical measurements with reduced reliance on advanced training. EDAN Nano OB Assist received CE marking on March 18, 2026, demonstrating compliance with European Union safety and performance requirements. As a new generation of AI-enabled ultrasound technology, this milestone underscores its readiness for clinical use and supports its potential to expand access to essential prenatal screening in underserved regions. Unlike conventional ultrasound systems that require skilled sonographers and complex workflows, EDAN Nano OB Assist is designed to support frontline healthcare providers by automating image analysis and delivering essential insights, including gestational age, fetal presentation, and estimated delivery date, etc. According to the World Health Organization, approximately 178,000 women in Africa die each year from pregnancy and childbirth-related complications, many of which are preventable. However, access to ultrasound — a critical tool in prenatal assessment — remains limited in many regions due to resource constraints and a shortage of trained professionals. During the event, EDAN demonstrated the device in a live, side-by-side comparison with a conventional ultrasound system, highlighting differences in workflow, time efficiency, and ease of use. The demonstration underscored the potential of AI-enabled scanning to support broader adoption of ultrasound in primary and community care settings. EDAN also highlighted its ongoing commitment to healthcare development in Africa through its Kenya office, which supports local partnerships, clinical training, and product implementation across the region. The launch of EDAN Nano OB Assist reflects EDAN's broader focus on developing accessible, clinically meaningful technologies that address real-world healthcare challenges. Announcement • Dec 31
Edan Instruments, Inc. to Report Fiscal Year 2025 Results on Mar 31, 2026 Edan Instruments, Inc. announced that they will report fiscal year 2025 results on Mar 31, 2026 Announcement • Sep 30
Edan Instruments, Inc. to Report Q3, 2025 Results on Oct 28, 2025 Edan Instruments, Inc. announced that they will report Q3, 2025 results on Oct 28, 2025 Announcement • Jul 02
Edan Instruments, Inc. to Report First Half, 2025 Results on Aug 26, 2025 Edan Instruments, Inc. announced that they will report first half, 2025 results on Aug 26, 2025 Announcement • Apr 25
Edan Instruments, Inc. Proposes Final Cash Dividend for 2024 Edan Instruments, Inc. proposed final cash dividend of CNY 2.07000000 per 10 shares (tax included) for 2024. Announcement • Apr 24
Edan Instruments, Inc., Annual General Meeting, May 15, 2025 Edan Instruments, Inc., Annual General Meeting, May 15, 2025, at 15:30 China Standard Time. Location: No. 15, Jinhui Road, Jinsha Community, Kengzi Subdistrict, Pingshan District, Shenzhen, Guangdong China Announcement • Mar 31
Edan Instruments, Inc. to Report Q1, 2025 Results on Apr 24, 2025 Edan Instruments, Inc. announced that they will report Q1, 2025 results on Apr 24, 2025 Announcement • Dec 31
Edan Instruments, Inc. to Report Fiscal Year 2024 Results on Apr 24, 2025 Edan Instruments, Inc. announced that they will report fiscal year 2024 results on Apr 24, 2025 Announcement • Nov 12
Edan Instruments, Inc. Unveils Latest Innovations for Global Healthcare at MEDICA 2024 Edan Instruments, Inc. showcased its latest product innovations at MEDICA 2024 in Germany. The event, held from November 11 to 14, attracted over 83,000 attendees and 5,300 exhibitors, highlighting advancements in healthcare technology. Marking 10 years in the blood gas field, EDAN officially reaching audiences with i500 this year, as one of the world's smallest benchtop analyzers with true zero maintenance, delivering over 30 parameters per test. The new Blood Sampler offers safer sampling with size options, ensuring accuracy by reducing ion interference via calcium-balanced heparin-lithium coating. Expanding in IVD, EDAN introduces the H90 Series hematology analyzer, utilizing 3D fluorescence technology for precise RET, DIFF and NRBC results. In ultrasound, EDAN highlighted the Acclarix AX9, a portable diagnostic ultrasound system featuring the cutting-edge SynSight zone sonography platform, which drew widespread attention for its robust performance as a powerful solution for diverse clinical settings. Alongside the AX9, the Nano Series handheld systems offer compact and user-friendly technology to meet the demand for high-quality, portable imaging. EDAN's F15 Series fetal and maternal monitors are trusted for their reliability and performance. Recognized by renowned institutions worldwide, the F15 continues to evolve based on client feedback, ensuring it meets the demands of modern obstetric care with precision and confidence. The PA4 Pro biofeedback system provides a portable solution for pelvic floor rehabilitation, receiving positive feedback from healthcare professionals. Additionally, the C12 UHD colposcope brings ultra-high-definition imaging with a 4K camera, delivering detailed visualization of lesion morphology and vascular characteristics for gynecological diagnostics. In patient monitoring, EDAN's upcoming iV100 is a versatile solution, functioning seamlessly as a multi-parameter module within the iV series, while also serving as a transport monitor and bedside monitor in one. Designed for use across diverse settings--from ambulances to hospitals--it ensures uninterrupted access to patient data, facilitating seamless, continuous and effective care. This commitment to adaptable, user-friendly design extends to cardiology. The soon-to-be-released SE-1202E 12-channel ECG features a high-resolution screen, and streamlined touch controls for easy cleaning and enhanced usability in cardiac diagnosis, while the new compact SE-310 ECG brings portability and efficiency to primary care. Reported Earnings • Oct 25
Third quarter 2024 earnings released: EPS: CN¥0.081 (vs CN¥0.051 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.081 (up from CN¥0.051 in 3Q 2023). Revenue: CN¥459.9m (up 6.1% from 3Q 2023). Net income: CN¥46.8m (up 57% from 3Q 2023). Profit margin: 10% (up from 6.9% in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Oct 15
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥10.39, the stock trades at a trailing P/E ratio of 43.2x. Average trailing P/E is 31x in the Medical Equipment industry in China. Total loss to shareholders of 1.6% over the past three years. Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 27% After last week's 27% share price gain to CN¥11.35, the stock trades at a trailing P/E ratio of 47.2x. Average trailing P/E is 31x in the Medical Equipment industry in China. Total returns to shareholders of 3.3% over the past three years. Announcement • Sep 30
Edan Instruments, Inc. to Report Q3, 2024 Results on Oct 25, 2024 Edan Instruments, Inc. announced that they will report Q3, 2024 results on Oct 25, 2024 Buy Or Sell Opportunity • Sep 19
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 1.9% to CN¥9.05. The fair value is estimated to be CN¥7.45, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 3.9% over the last 3 years. Earnings per share has declined by 14%. New Risk • Sep 18
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 34% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.0% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (7.9% net profit margin). Announcement • Jun 29
Edan Instruments, Inc. to Report First Half, 2024 Results on Aug 30, 2024 Edan Instruments, Inc. announced that they will report first half, 2024 results on Aug 30, 2024 Reported Earnings • Apr 26
First quarter 2024 earnings released: EPS: CN¥0.066 (vs CN¥0.24 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.066 (down from CN¥0.24 in 1Q 2023). Revenue: CN¥443.6m (down 31% from 1Q 2023). Net income: CN¥38.5m (down 73% from 1Q 2023). Profit margin: 8.7% (down from 22% in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings. Announcement • Mar 30
Edan Instruments, Inc. to Report Q1, 2024 Results on Apr 26, 2024 Edan Instruments, Inc. announced that they will report Q1, 2024 results on Apr 26, 2024 Announcement • Mar 29
Edan Instruments, Inc., Annual General Meeting, Apr 22, 2024 Edan Instruments, Inc., Annual General Meeting, Apr 22, 2024, at 15:30 China Standard Time. Location: No. 15, Jinhui Road, Jinsha Community, Kengzi Subdistrict, Pingshan District, Shenzhen, Guangdong China Reported Earnings • Mar 29
Full year 2023 earnings released: EPS: CN¥0.38 (vs CN¥0.40 in FY 2022) Full year 2023 results: EPS: CN¥0.38 (down from CN¥0.40 in FY 2022). Revenue: CN¥1.94b (up 11% from FY 2022). Net income: CN¥221.3m (down 5.0% from FY 2022). Profit margin: 11% (down from 13% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings. New Risk • Mar 25
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 9.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (9.7% average weekly change). Valuation Update With 7 Day Price Move • Mar 18
Investor sentiment improves as stock rises 33% After last week's 33% share price gain to CN¥12.56, the stock trades at a trailing P/E ratio of 26x. Average trailing P/E is 30x in the Medical Equipment industry in China. Total loss to shareholders of 22% over the past three years. Valuation Update With 7 Day Price Move • Feb 05
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥7.55, the stock trades at a trailing P/E ratio of 15.6x. Average trailing P/E is 24x in the Medical Equipment industry in China. Total loss to shareholders of 48% over the past three years. Announcement • Dec 30
Edan Instruments, Inc. to Report Fiscal Year 2023 Results on Mar 29, 2024 Edan Instruments, Inc. announced that they will report fiscal year 2023 results on Mar 29, 2024 Announcement • Nov 15
Edan Instruments, Inc. Focus on Medical Technology Advancement Shines At Medica 2023 Edan Instruments, Inc. showcased its innovative range of new products at MEDICA 2023 in Germany. This grand event, anticipated to draw over 81,000 visitors and host 4,500 exhibitors from around the globe, took place from November 13 to 16. Highlighting the new addition to its product lineup, EDAN introduced three gynecology products, showcasing its ongoing progress and reinforcing its status as a forefront technology leader in enhancing women's healthcare. Of noteworthy mention is the overseas debut of the Q andS Series handheld biofeedback and stimulation system, extending its current portfolio and adding valuable rehabilitation applications to its offerings, drawing significant interest from attendees. In the ultrasound section, two ready-to-launch products, the Nano Series handheld ultrasound systems and the Acclarix AX9, the portable diagnostics ultrasound system, convey freshness to the audiences. The designs combine portability and functionality, bringing in a user-friendly cutting-edge technology operation practice. The iV Series, EDAN's newly launched modular monitor, amazed the audiences with its innovative parameters, including the PresCCO continuous cardiac output, which gives doctors patients critical cardiac function parameters in real-time. The product has also been developed with high-standard parameters and clinical assistive applications for acute care. Caregivers can use authoritative tools to make decisions quickly in all ranges of acuity areas. The new telemetry systems, iT30 and iT50, which have attracted a lot of attention from clients, also met the audience on-site for the first time. For the laboratory sector, EDAN presents a full picture of its POCT&IVD innovations, including the i500, the ready-to-launch blood gas and chemistry analyzer, which provides all the benchtop features with a small footprint. In the veterinary field, EDAN's latest hematology product, H90X Vet, responds to the increasing demand for testing and has sparked keen interest among a larger number of veterinary departments and laboratories. New Risk • Oct 25
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 21% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Reported Earnings • Oct 25
Third quarter 2023 earnings released: EPS: CN¥0.051 (vs CN¥0.068 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.051 (down from CN¥0.068 in 3Q 2022). Revenue: CN¥433.6m (up 13% from 3Q 2022). Net income: CN¥29.8m (down 24% from 3Q 2022). Profit margin: 6.9% (down from 10% in 3Q 2022). Reported Earnings • Aug 23
Second quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.17 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.12 (down from CN¥0.17 in 2Q 2022). Revenue: CN¥450.3m (down 3.8% from 2Q 2022). Net income: CN¥66.6m (down 34% from 2Q 2022). Profit margin: 15% (down from 22% in 2Q 2022). The decrease in margin was primarily driven by higher expenses. Announcement • Jul 01
Edan Instruments, Inc. to Report First Half, 2023 Results on Aug 23, 2023 Edan Instruments, Inc. announced that they will report first half, 2023 results on Aug 23, 2023 Reported Earnings • Apr 28
First quarter 2023 earnings released: EPS: CN¥0.24 (vs CN¥0.085 in 1Q 2022) First quarter 2023 results: EPS: CN¥0.24 (up from CN¥0.085 in 1Q 2022). Revenue: CN¥639.7m (up 64% from 1Q 2022). Net income: CN¥140.4m (up 183% from 1Q 2022). Profit margin: 22% (up from 13% in 1Q 2022). The increase in margin was driven by higher revenue. Valuation Update With 7 Day Price Move • Dec 19
Investor sentiment deteriorated over the past week After last week's 18% share price decline to CN¥12.13, the stock trades at a trailing P/E ratio of 41.3x. Average trailing P/E is 34x in the Medical Equipment industry in China. Total loss to shareholders of 9.3% over the past year. Reported Earnings • Oct 27
Third quarter 2022 earnings released: EPS: CN¥0.068 (vs CN¥0.11 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.068 (down from CN¥0.11 in 3Q 2021). Revenue: CN¥384.0m (up 2.9% from 3Q 2021). Net income: CN¥39.3m (down 40% from 3Q 2021). Profit margin: 10% (down from 18% in 3Q 2021). The decrease in margin was driven by higher expenses. Valuation Update With 7 Day Price Move • Oct 15
Investor sentiment improved over the past week After last week's 18% share price gain to CN¥14.83, the stock trades at a trailing P/E ratio of 43.7x. Average trailing P/E is 35x in the Medical Equipment industry in China. Total returns to shareholders of 35% over the past year. Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improved over the past week After last week's 22% share price gain to CN¥12.69, the stock trades at a trailing P/E ratio of 37.4x. Average trailing P/E is 30x in the Medical Equipment industry in China. Total returns to shareholders of 12% over the past year. Reported Earnings • Aug 25
Second quarter 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.10 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.17 (up from CN¥0.10 in 2Q 2021). Revenue: CN¥468.1m (up 24% from 2Q 2021). Net income: CN¥100.9m (up 67% from 2Q 2021). Profit margin: 22% (up from 16% in 2Q 2021). The increase in margin was driven by higher revenue. Board Change • May 31
High number of new directors Independent Director Quanlu Zheng was the last director to join the board, commencing their role in 2022. Board Change • Apr 29
High number of new directors Independent Director Quanlu Zheng was the last director to join the board, commencing their role in 2022. Reported Earnings • Apr 27
First quarter 2022 earnings released: EPS: CN¥0.085 (vs CN¥0.21 in 1Q 2021) First quarter 2022 results: EPS: CN¥0.085 (down from CN¥0.21 in 1Q 2021). Revenue: CN¥389.6m (down 24% from 1Q 2021). Net income: CN¥49.6m (down 60% from 1Q 2021). Profit margin: 13% (down from 25% in 1Q 2021). The decrease in margin was driven by lower revenue. Valuation Update With 7 Day Price Move • Jan 22
Investor sentiment deteriorated over the past week After last week's 19% share price decline to CN¥11.90, the stock trades at a trailing P/E ratio of 25.6x. Average trailing P/E is 36x in the Medical Equipment industry in China. Total loss to shareholders of 31% over the past year. Reported Earnings • Oct 28
Third quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.28 in 3Q 2020) The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥373.2m (down 40% from 3Q 2020). Net income: CN¥65.8m (down 60% from 3Q 2020). Profit margin: 18% (down from 26% in 3Q 2020). The decrease in margin was driven by lower revenue. Reported Earnings • Aug 24
Second quarter 2021 earnings released: EPS CN¥0.10 (vs CN¥0.67 in 2Q 2020) The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥376.7m (down 59% from 2Q 2020). Net income: CN¥60.5m (down 85% from 2Q 2020). Profit margin: 16% (down from 43% in 2Q 2020). The decrease in margin was driven by lower revenue. Reported Earnings • Apr 27
First quarter 2021 earnings released: EPS CN¥0.21 (vs CN¥0.14 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥509.3m (up 42% from 1Q 2020). Net income: CN¥124.5m (up 53% from 1Q 2020). Profit margin: 25% (up from 23% in 1Q 2020). The increase in margin was driven by higher revenue. Reported Earnings • Mar 15
Full year 2020 earnings released: EPS CN¥1.12 (vs CN¥0.23 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥2.32b (up 104% from FY 2019). Net income: CN¥653.2m (up 395% from FY 2019). Profit margin: 28% (up from 12% in FY 2019). The increase in margin was driven by higher revenue. Valuation Update With 7 Day Price Move • Feb 08
Investor sentiment deteriorated over the past week After last week's 15% share price decline to CN¥14.44, the stock is trading at a trailing P/E ratio of 12.8x, down from the previous P/E ratio of 15.1x. This compares to an average P/E of 43x in the Medical Equipment industry in China. 
